Uncategorized
FDA clears IND application for Aura Biosciences’ AU-011 for ocular melanoma
The FDA has cleared an investigational new drug application for light-activated AU-011 in ocular melanoma, allowing clinical testing to begin, according to a press release from Aura Biosciences.AU-011 is a targeted therapy administered through an intravitreal injection and consists of viral nanoparticle conjugates that bind to cancer cells in the eye. The drug is then activated with an ophthalmic laser, destroying the membranes of tumor cells.